A new approach for neurodegenerative diseases

Innovative technology

AmyPore is a Biotechnology company that designs therapeutic peptides with the aim of developing treatments for neurodegenerative diseases: Alzheimer's disease & Parkinson's disease.


New therapeutic strategy

Alzheimer & Parkinson

Our main product, AmyP53, is a therapeutic peptide derived from scientific research.

Its design is based on an innovative strategy based on molecular modeling applied to neuroscience. This strategy has made it possible to combine, in a multi-parameter specification: targeting of a fundamental mechanism common to Alzheimer's and Parkinson's diseases, low-dose therapeutic action, absence of side effects at this stage of the research, administration not invasive (nasal spray).

AmyP53 is the first representative of a new therapeutic class capable of treating Alzheimer’s and Parkinson’s diseases.

20 years of Neuroscience Research
2 renowned inventors

Pr. Nouara Yahi
Pr. Jacques Fantini
New target

Neurotoxic oligomers
Administered by nasal spray
Deployable on a global scale
A unique strategy for 2 diseases

Alzheimer & Parkinson

Our approach

An innovative strategy resulting from neuroscience research

Understanding the mechanisms responsible for Alzheimer’s and Parkinson’s diseases to lead us to innovative treatments. Develop a new therapeutic class.

Our concept:

New therapeutic target

The AmyP53 solution

Scientific publications

AmyP53 is active on neurons and astrocytes 

AmyP53 is active on neurons and astrocytes 

Who are we ?

AmyPore is a Biotech founded in 2018 on the basis of the scientific discoveries of Pr. Nouara Yahi and Jacques Fantini, researchers in molecular neuroscience at the University of Aix-Marseille. 

Our sponsors

AmyPore is supported by the European Commission, Kedge Business School and the inter-university incubator IMPULSE. 

The company obtained a grant H2020 SME Phase 1.


Follow all our news



AmyPore presents its latest results at the International AD/PD Congress in Lisbon 2024

Press release

Next to come